Revolution Medicines reported that daraxonrasib met key survival endpoints in a Phase 3 trial in metastatic pancreatic ductal adenocarcinoma, with results that nearly doubled outcomes versus standard chemotherapy at an early checkpoint. The company said patients receiving the daily KRAS-family inhibitor lived a median of 13.2 months compared with 6.7 months in the chemotherapy arm, prompting Revolution to end the study early. Revolution also pointed to an FDA “national priority” voucher already awarded for daraxonrasib, which could accelerate review timelines after an official submission. The company said it plans to file for regulatory action following the next steps that usually follow Phase 3 readouts. The update increases competitive pressure in pancreatic cancer, where durable survival gains have remained scarce and RAS-pathway drugs are drawing heightened attention.